166 related articles for article (PubMed ID: 21372825)
1. Sesquiterpenoids from myrrh inhibit androgen receptor expression and function in human prostate cancer cells.
Wang XL; Kong F; Shen T; Young CY; Lou HX; Yuan HQ
Acta Pharmacol Sin; 2011 Mar; 32(3):338-44. PubMed ID: 21372825
[TBL] [Abstract][Full Text] [Related]
2. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells.
Nakka M; Agoulnik IU; Weigel NL
Int J Biochem Cell Biol; 2013 Apr; 45(4):763-72. PubMed ID: 23270728
[TBL] [Abstract][Full Text] [Related]
3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
4. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH
Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633
[TBL] [Abstract][Full Text] [Related]
5. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.
Hu YC; Yeh S; Yeh SD; Sampson ER; Huang J; Li P; Hsu CL; Ting HJ; Lin HK; Wang L; Kim E; Ni J; Chang C
J Biol Chem; 2004 Aug; 279(32):33438-46. PubMed ID: 15166229
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
7. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
8. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.
Zhu ML; Horbinski CM; Garzotto M; Qian DZ; Beer TM; Kyprianou N
Cancer Res; 2010 Oct; 70(20):7992-8002. PubMed ID: 20807808
[TBL] [Abstract][Full Text] [Related]
9. Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.
Trtkova K; Paskova L; Matijescukova N; Strnad M; Kolar Z
Neoplasma; 2010; 57(5):406-14. PubMed ID: 20568894
[TBL] [Abstract][Full Text] [Related]
10. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.
Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW
Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
Weissenrieder JS; Reilly JE; Neighbors JD; Hohl RJ
Prostate; 2019 Jan; 79(1):21-30. PubMed ID: 30106164
[TBL] [Abstract][Full Text] [Related]
12. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
Hsu JC; Zhang J; Dev A; Wing A; Bjeldanes LF; Firestone GL
Carcinogenesis; 2005 Nov; 26(11):1896-904. PubMed ID: 15958518
[TBL] [Abstract][Full Text] [Related]
13. In vitro gene expression changes of androgen receptor coactivators after hormone deprivation in an androgen-dependent prostate cancer cell line.
Chang HC; Chen SC; Chen J; Hsieh JT
J Formos Med Assoc; 2005 Sep; 104(9):652-8. PubMed ID: 16276440
[TBL] [Abstract][Full Text] [Related]
14. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform.
Alen P; Claessens F; Schoenmakers E; Swinnen JV; Verhoeven G; Rombauts W; Peeters B
Mol Endocrinol; 1999 Jan; 13(1):117-28. PubMed ID: 9892017
[TBL] [Abstract][Full Text] [Related]
16. [Effect of compound Chinese traditional medicine PC-SPES II in inhibiting proliferation of human prostate cancer cell LNCaP and on expressions of AR and PSA].
Zhang BY; Li YF; Lai Y; Li YS; Chen ZJ
Zhongguo Zhong Yao Za Zhi; 2015 Mar; 40(5):950-6. PubMed ID: 26087562
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
18. The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.
Moss PE; Lyles BE; Stewart LV
Exp Cell Res; 2010 Dec; 316(20):3478-88. PubMed ID: 20932825
[TBL] [Abstract][Full Text] [Related]
19. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
Shi XB; Xue L; Zou JX; Gandour-Edwards R; Chen H; deVere White RW
Prostate; 2008 Dec; 68(16):1816-26. PubMed ID: 18780293
[TBL] [Abstract][Full Text] [Related]
20. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
